This activity is provided by Albert Einstein College of Medicine of Yeshiva University in collaboration with Haymarket Medical Education (HME).
This activity is supported by an educational grant from Lilly.
An older patient who complains of occasional forgetfulness but is otherwise able to function normally may be an example of the “worried well” or may in fact be in an early stage of Alzheimer’s disease (AD). Current research suggests that early intervention aimed at slowing symptom progression may be more successful than later attempts to treat individuals who are already experiencing more significant cognitive deficits.
Neurologists and other healthcare professionals who provide care for patients with or at risk for AD and related dementias
After participating in this activity, practitioners should be better able to:
Identify the clinical relevance of ongoing research on treatment approaches to AD
Initiate measures intended to delay or slow the progression of AD in patients who may be at risk or are exhibiting signs suggesting early disease
Identify resources and strategies to provide a continuum of care for patients and their caregivers while patients are in the early stages of, or at risk for, AD
Conflict Of Interest Disclosure Policy
It is the policy of Albert Einstein College of Medicine of Yeshiva University to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty participating in our programs are expected to disclose any relationships they may have with commercial companies whose products or services may be mentioned, so that participants may evaluate the objectivity of the presentations. In addition, any discussion of off-label, experimental, or investigational uses of drugs or devices will be disclosed by the faculty.
Course Director Victor B. Hatcher, PhD Professor of Medicine and Biochemistry Montefiore Medical Center Bronx, NY
Dr. Hatcher has nothing to disclose.
Peer Reviewer Gary Kennedy, MD Professor of Psychiatry Montefiore Medical Center Bronx, NY
Dr. Kennedy has received grant/research support from Lilly.
Faculty Bradford C. Dickerson, MD Associate Professor of Neurology Harvard Medical School Director of Clinical Applications, Morphometry Service Director, Frontotemporal Disorders Unit Massachusetts General Hospital Co-Director, Neuroimaging Group, Gerontology Research Unit Boston, MA
Dr. Dickerson received royalties from Oxford University Press for the book Dementia: Comprehensive Care and Practice, and he is a consultant to Merck, FORUM Pharmaceuticals, and Isis Pharmaceuticals.
Martin R. Farlow, MD Professor and Vice Chairman of Research Department of Neurology Associate Director Indiana Alzheimer Disease Center Indiana University School of Medicine Indianapolis, IN
Dr. Farlow serves as a consultant for Accera, Alltech, Avanir, Biogen, Eisai Medical Research, Inc., Eli Lilly, FORUM Pharmaceuticals, GliaCure, Grifols, Helicon, INC Research, Lundbeck, MedAvante, Medivation, Inc., Merck & Co., Inc., Novartis, Pfizer, Prana Biotechnology, QR Pharma, Roche, Sanofi-Aventis, Schering-Plough, Taisho Toyama Pharmaceutical Co., Takeda, and UCB. He also serves on the speakers’ bureaus for Eisai, Eli Lilly, Forest, Pfizer, and Novartis and has received grant/research support from Accera, Biogen, Chase Pharmaceuticals, Eisai, Eli Lilly, Genentech, Lundbeck, and Roche. Dr. Farlow has a patent that is licensed to Elan.
Accredited Provider Disclosure
The staff of the Center for Continuing Medical Education of Albert Einstein College of Medicine of Yeshiva University has no disclosures to report with any commercial interests relative to this CME activity.
Planners' and Managers' Disclosures
Jill Rovitzky Black, Margot Embree Fisher, and Sarah Taegder of Haymarket Medical Education have nothing to disclose with regard to commercial support.
AMA PRA Category 1 Credit(s)TM
Albert Einstein College of Medicine of Yeshiva University is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Albert Einstein College of Medicine of Yeshiva University designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Lilly, Albert Einstein College of Medicine of Yeshiva University, and Haymarket Medical Education do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Eli Lilly, Albert Einstein College of Medicine of Yeshiva University, or Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
To obtain credit, a score of 70% or better is required. This CME is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/CME History, which you can then access at any time.